Skip Navigation

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Direskeneli, H.
Right arrow Articles by Akoglu, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Direskeneli, H.
Right arrow Articles by Akoglu, E.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Nephrol Dial Transplant (1992) 7: 422-426
© 1992 European Renal Association-European Dialysis and Transplant Association

research-article

Anti-lymphocyte, anti-monocyte, and anti-endothelial cell antibodies in chronic haemodialysis patients

H. Direskeneli1, S. Özgün1, C. Özener1, R. Lawrence1, M. Erman2, N. Sarsmaz3 and E. Akoglu1,

1Marmara University Hospital Istanbul, Turkey 2Turkish Transplantation and Burn Foundation Centre Istanbul, Turkey 3Ren-Med Haemodialysis Centre Istanbul, Turkey

Correspondence and offprint requests to: Professor E. Akoglu, Department of Nephrology, Marmara University Hospital, Altunizade, Istanbul, Turkey

Patients receiving chronic haemodialysis treatment are known to have a high prevalence of anti-panel antibodies (anti-lymphocyte, antimonocyte, and anti-endothelial cell) originating from a number of different possible sensitizing events such as blood transfusions, multiparity, or renal transplantation. In this study the prevalence of these antibodies in 123 chronic haemodialysis patients was evaluated. Anti-lymphocyte antibodies and anti-monocyte antibodies were found in 27.6% and 21.9% of the patient group respectively. Following exclusion of twelve patients within the study population with a history of previous graft rejection, anti-monocyte antibodies were encountered more frequently in transfused patients than those never having been transfused (22.4% versus 0%, P<0.05), whilst the prevalence of anti-lymphocyte antibodies was similar in both groups (28.2% versus 19.2%). Multiparity, patient age, or duration of dialysis treatment could not be demonstrated to significantly alter the prevalence of either of these antibodies. Of 12 patients with an episode of previous graft rejection, eight were positive for anti-monocyte antibodies and five for antilymphocyte antibodies. Anti-endothelial cell antibodies were common in patients in this group, being present in seven of eight individuals investigated.

Keywords: panel-reactive antibodies; chronic haemodialysis; transfusion; sensitization


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 LupusHome page
Y. Adler, K. Salozhin, M. Le Tonqueze, Y. Shoenfeld, and P. Youinou
Review: Anti-Endothelial Cell Antibodies: a Need for Standardization
Lupus, April 1, 1994; 3(2): 77 - 84.
[Abstract] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.